CAJ | 학술논문

骨髓间充质干细胞(MSC)在体内具有向肿瘤部位定向迁移能力,是比较理想的基因治疗"细胞载体".通过转染或转导的方法,在体外使MSC携带目的基因,并获得稳定表达,然后将它们移植到宿主体内,发挥治疗作用.这种先体外后体内的过程在胶质瘤等多个系统肿瘤中进行了研究,获得阳性结果.MSC移植的安全性值得关注,其中与宿主肿瘤细胞的相互作用目前尚无定论.
골수간충질간세포(MSC)재체내구유향종류부위정향천이능력,시비교이상적기인치료"세포재체".통과전염혹전도적방법,재체외사MSC휴대목적 기인,병획득은정표체,연후장타문이식도숙주체내,발휘치료작용.저충선체외후체내적과정재효질류등다개계통종류중진행료연구,획득양성결과.MSC이식적안전성치득관주,기중여숙주종류세포적상호작용목전상무정론.
Bone marrow-derived mesenchymal stem cells (MSCs) are capable of migrating and homing to brain tumors in vivo and therefore is a promising targeted-delivery vehicle in cancer gene therapy. MSCs are transfected or transducted with the therapeutic genes and achieve stable expression in vitro, then are delivered to the host to exert their therapeutic effects. The Ex Vivo gene transfer of MSCs has been studied in several types of tumors including gliomas, and results were postive. The safety of MSC-based gene delivery remains to be controversial. The interactions between MSCs and host tumor cells need to be investigated.